Circulation Article Reports That Medtronic, Inc.'s Endeavor(R) Drug-Eluting Stent Provides Further Evidence Of Effective, Safe And Sustained Clinical Outcomes

MINNEAPOLIS--(BUSINESS WIRE)--Aug. 21, 2006--Medtronic, Inc. (NYSE:MDT): ENDEAVOR II Shows Impressive Reduction in Repeat Procedures and Vessel Re-Narrowing for Patients with Coronary Artery Disease